{"entity":{"id":"prestige-biopharma","kind":"company","name":"Prestige Biopharma","aka":["Prestige BioPharma Limited","KRX:950210"],"tldr":"Prestige Biopharma is a Singapore-based antibody company, listed in Korea, that makes biosimilars and is developing PBP1510, a first-in-class antibody against the pancreatic cancer protein PAUF.","summary":"Prestige Biopharma develops biosimilars, including trastuzumab (Tuznue) and bevacizumab candidates, and novel antibodies. PBP1510 (ulenistamab) neutralises pancreatic adenocarcinoma up-regulated factor (PAUF), a secreted protein that drives tumour growth and immune evasion; it has orphan designations in the United States and Europe and is in a phase 1/2a trial with gemcitabine in advanced pancreatic cancer. The company also develops PBP1710 against CTHRC1.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.prestigebiopharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["pbp1510"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Singapore","country":"SG","companyType":"biotech","website":"https://www.prestigebiopharma.com/","ticker":"KRX:950210","stage":"public","investors":[],"funding":[]},"route":"/companies/prestige-biopharma/","neighbours":{"drug":[{"id":"pbp1510","kind":"drug","name":"PBP1510","route":"/drugs/pbp1510/"}]}}